Malini M Gandhi

9PUBLICATIONS
161CO-AUTHORS
Innate immunityPredictive and prognostic markersMolecular targetsCancer therapy (excl. chemotherapy and radiation therapy)Cardiology (incl. cardiovascular diseases)
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (9)

|Sep 04, 2025
Immunoprofiling at an Institutional Scale Reveals That High Numbers of Intratumoral CD8+ and PD-1+ Cells Predict Superior Patient Survival Across Major Cancer Types Independent of Major Risk Factors.

Joao V Alessi, James R Lindsay, Anita Giobbie-Hurder

|Apr 18, 2025
Factors Associated with Disease Progression after Discontinuation of Immune Checkpoint Inhibitors for Immune-Related Toxicity in Patients with Advanced Non-Small Cell Lung Cancer.

Federica Pecci, Rohit Thummalapalli, Stephanie L Alden

|Apr 09, 2025
Antitumor Activity of Vebreltinib and Characterization of Clinicogenomic Features in Solid Tumors with MET Rearrangements.

Seshiru Nakazawa, Federica Pecci, Igor Odintsov

|Oct 07, 2024
Response to Crizotinib After Entrectinib Resistance in ROS1-Rearranged, MET-Amplified Lung Adenocarcinoma.

Victor R Vaz, Malini M Gandhi, Biagio Ricciuti

|Apr 02, 2024
Activating Point Mutations in the MET Kinase Domain Represent a Unique Molecular Subset of Lung Cancer and Other Malignancies Targetable with MET Inhibitors.

Federica Pecci, Seshiru Nakazawa, Biagio Ricciuti

|Jan 11, 2024
Genomic and Immunophenotypic Landscape of Acquired Resistance to PD-(L)1 Blockade in Non-Small-Cell Lung Cancer.

Biagio Ricciuti, Giuseppe Lamberti, Sreekar R Puchala

Pageof 2

Frequent Collaborators

8 joint publications

Biagio Ricciuti

8 joint publications

Mark M Awad

7 joint publications

Joao V Alessi

7 joint publications

Alessandro Di Federico